A quantitative comparison of dual control of a hormone response element of progestins and glucocorticoids in the same cell line

Progesterone receptor-containing T47D human breast cancer cells are responsive to progestins but fail to respond to other steroid hormones, in particular dexamethasone, because they have no measurable levels of receptors for estrogens, androgens, or glucocorticoids. To quantitatively study dual resp...

Full description

Saved in:
Bibliographic Details
Published inMolecular endocrinology (Baltimore, Md.) Vol. 3; no. 8; pp. 1270 - 1278
Main Authors NORDEEN, S. K, KUÊHNEL, B, LAWLER-HEAVNER, J, BARBER, D. A, EDWARDS, D. P
Format Journal Article
LanguageEnglish
Published Bethesda, MD Endocrine Society 01.08.1989
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Progesterone receptor-containing T47D human breast cancer cells are responsive to progestins but fail to respond to other steroid hormones, in particular dexamethasone, because they have no measurable levels of receptors for estrogens, androgens, or glucocorticoids. To quantitatively study dual responsiveness of the mouse mammary tumor virus (MMTV) promoter to progestins and glucocorticoids, we have stably transfected T47D cells with a glucocorticoid receptor (GR) expression vector. A cloned derivative (A1-2) was isolated that expresses a normal, full length GR, as assessed by steroid binding and Western immunoblot with a monoclonal anti-GR antibody. Moreover, GR is expressed at levels (80,000-100,000 molecules per cell) comparable to the high levels of endogenous progesterone receptor (200,000 molecules per cell). In A1-2 cells transiently transfected with an MMTV-chloramphenicol acetyl transferase reporter gene, induction by glucocorticoid was substantially greater (5-fold) than induction mediated by progestins. These results suggest that glucocorticoids may be the primary regulator of MMTV.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0888-8809
1944-9917
DOI:10.1210/mend-3-8-1270